

CTI - PharmacoEconomics February 2010

Adis Clinical Trials Insight: Presented at Meetings - PharmacoEconomics

The table below highlights some of trials presented during sessions at the meetings described.

2010 Gastrointestinal Cancers Symposium (January 2010 : Orlando, Florida, USA)

Adis CTI Record	Drug(s)	Purpose	Study Results	Sponsor
1 803005944	Sorafenib	This study compared the cost effectiveness of sorafenib versus best supportive care (BSC) for the treatment of patients with unresectable hepatocellular carcinoma in Singapore.	Sorafenib appeared to be cost effective compared with best supportive care (BSC) for the treatment of patients with unresectable hepatocellular carcinoma in Singapore. Sorafenib had an incremental cost per life-year gained of S\$113,217 compared with BSC.	Bayer HealthCare Pharmaceuticals
2 803005979	Antineoplastics Gemcitabine	This study compared the cost effectiveness of neoadjuvant weekly gemcitabine + low- or high-dose radiotherapy, adjuvant chemotherapy + radiotherapy, and adjuvant gemcitabine for the treatment of patients with resectable pancreatic cancer in the USA.	Neoadjuvant chemotherapy + radiotherapy appeared to be cost effective compared with adjuvant gemcitabine for the treatment of patients with resectable pancreatic cancer in the USA. Compared with adjuvant gemcitabine, the neoadjuvant chemotherapy + high-dose radiotherapy and the neoadjuvant chemotherapy + low-dose radiotherapy strategies had incremental costs per life-year gained of \$US30,028 and \$US15,566, respectively.	
3 803005991		This study compared the cost effectiveness of the guaiac faecal occult blood test (gFOBT) and a qualitative faecal immunochemical test (with different cut-off haemoglobin levels for referral for colonoscopy) for the diagnosis of colorectal cancer in The Netherlands.	A qualitative faecal immunochemical test (FIT) appeared to be more effective and less costly (dominant) than guaiac faecal occult blood test (gFOBT) for the diagnosis of colorectal cancer (followed by referral for colonoscopy) in The Netherlands. The FIT cut-off level of 50 ng/mL haemoglobin for referral for colonoscopy was more cost-effective than the higher cutoff levels. Biennial screening between ages 55 and 75 resulted in an incremental cost per life-year gained of EUR3,900. [CONT.]	
4 803005974	Cetuximab Fluorouracil Folinic-acid Irinotecan Oxaliplatin	This study investigated the cost effectiveness of the addition of cetuximab to either fluorouracil + folinic acid + oxaliplatin (FOLFOX) or fluorouracil + folinic acid + irinotecan (FOLFIRI) for the first-line treatment of patients with metastatic colorectal cancer (mCRC) following resection of liver metastases in the UK.	The addition of cetuximab to either fluorouracil + folinic acid + irinotecan (FOLFIRI) or fluorouracil + folinic acid + oxaliplatin (FOLFOX) appeared to be cost effective compared with FOLFIRI and FOLFOX alone for the first-line treatment of patients with metastatic colorectal cancer following resection of liver metastases in the UK. Compared with FOLFIRI and FOLFOX alone, the addition of cetuximab resulted in incremental costs per quality-adjusted life-year gained of GBP19,557 and GBP21,056, respectively.	Merck Serono

CTI - PharmacoEconomics February 2010

Adis CTI Record	Drug(s)	Purpose	Study Results	Sponsor
5 803005717	Capecitabine Cisplatin Fluorouracil Trastuzumab	This study compared the effects on quality of life (QOL) of fluorouracil or capecitabine + cisplatin +/- trastuzumab when administered for the first-line treatment of patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer.	Capecitabine or fluorouracil + cisplatin +/- trastuzumab improved quality of life (QOL) from baseline when administered as first-line treatment in patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer. QOL Questionnaire Core-30 Items (QLQ-C30) Global Health Status scores increased during treatment in both arms, and showed further improvement after completion of treatment (trastuzumab arm from 55 to 64 to 72 and non-trastuzumab arm from 55 to 61 to 71).	Roche
Annual San Antonio Breast Cancer Symposium (32nd : December 2009 : San Antonio, Texas, USA)				
6 803006008	Anastrozole Goserelin Tamoxifen Zoledronic-acid	This study compared the cost effectiveness goserelin + anastrozole or tamoxifen +/- zoledronic acid for the treatment of premenopausal women with hormone-receptor-positive early breast cancer from the perspectives of the healthcare systems in Sweden, Norway, Denmark, and Finland.	Goserelin + anastrozole or tamoxifen + zoledronic acid appeared to be cost effective compared with goserelin + anastrozole or tamoxifen for the treatment of premenopausal women with hormone receptor-positive early breast cancer in in Sweden, Norway, Denmark, and Finland. The addition of zoledronic acid resulted in incremental costs per quality-adjusted life-year gained of EUR1510, EUR2162, EUR3369 and EUR3494 for Norway, Sweden, Finland and Denmark, respectively.	Novartis Pharmaceuticals Corporation

Adis Clinical Trials Insight: Ongoing Trials – Status Tracking February 2010

The table below highlights the Large (>100), Randomised Phase III & IV ongoing trials whose status has changed during February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
1 700024334		Completed	IV	Musculoskeletal pain: treatment Cost-utility analysis Manual treatment vs advice promoting self management in Denmark	
2 700014595		Active, no longer recruiting	III	Deep vein thrombosis: treatment Assessing cost-effectiveness of elastic compression stockings	SIGVARIS Corp
3 700043890		Recruiting	IV	Bipolar disorders: treatment Cost-effectiveness and quality-of-life effects of a chronic care management	
4 700046415		Active, no longer recruiting	IV	Uterine leiomyoma: treatment Cost-analysis trial of ExAblate surgery compared with myomectomy for the enhancement of fertility	InSightec

CTI - PharmacoEconomics February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
				In women with unexplained infertility and who have non-hysteroscopically resectable disease	
5 700041315		Completed	III	Prostate cancer: treatment Comparing cost-effectiveness of radical prostatectomy versus palliative expectant management In patients with clinically localised disease	
6 700050232		Discontinued	IV	Dementia: treatment Evaluating impact of dementia advisors on the quality of life of dementia sufferers Comparing cost-effectiveness of dementia advisor program with information provision alone	
7 700051273		Recruiting	IV	Bronchiolitis: treatment Comparing continuous versus intermittent pulse oxymetry on hospital cost and length of stay in neonates and infants	
8 700051882		Recruiting	IV	Back pain, sciatica: treatment Efficacy and costs of spinal cord stimulation with Precision SCS system versus reoperation In patients with failed back surgery syndrome; EVIDENCE trial	Boston Scientific Corporation
9 700047392		Active, no longer recruiting	IV	Stroke: treatment Assessing cost-effectiveness of a structured, training programme for caregivers to improve patient outcomes	
10 700051581	ACE-inhibitors Angiotensin-receptor-antagonists Bisoprolol Carvedilol	Recruiting	IV	Angiotensin receptor antagonists, ACE inhibitors, bisoprolol, carvedilol: therapeutic use Heart failure Improving prescribing patterns in heart failure patients by providing active specialist support and educational material to primary care physicians	
11 700051431	Alternative-medicine	Recruiting	IV	Depressive disorders: treatment Efficacy and cost-effectiveness of acupuncture, counselling Compared with usual general practitioner care	
12 700031925	Analgesics	Completed	IV	Analgesics: therapeutic use Musculoskeletal pain Evaluating prescribing patterns in patients with chronic disease: Efficacy, cost-effectiveness and resource use	

CTI - PharmacoEconomics February 2010

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
13 700033460	Antihypertensives Candesartan-cilexetil Chlortalidone Hydrochlorothiazide Indapamide Losartan Losartan/hydrochlorothiazide Olmesartan-medoxomil Telmisartan Trichlormethiazide Valsartan	Recruiting	III	Losartan/hydrochlorothiazide vs antihypertensives: therapeutic use Hypertension Phase III trial focusing on patient compliance: the COMFORT trial	
14 700039449	Antineoplastics	Recruiting	III	Antineoplastics: treatment Colorectal cancer Phase III trial alone or in combination with surgery in patients with asymptomatic metastatic disease: Cost-analysis	
15 700048117	Antiparkinsonians	Active, no longer recruiting	IV	Antiparkinsonians: therapeutic use Parkinsonism, essential tremor Assessing changes in prescribing pattern after DaTSCAN™ imaging in patients with clinically uncertain disease	GE Healthcare
16 700040216	Human-papillomavirus-vaccine-recombinant-quadrivalent	Recruiting	III	Human papillomavirus vaccine recombinant quadrivalent: therapeutic use Prevention of human papillomavirus infections, cervical cancer Phase III trial in underserved African American adolescent females: Drug-utilisation trial	Merck & Co
17 70005522	Ibandronic-acid Zoledronic-acid	Completed	III	Ibandronic acid vs zoledronic acid: therapeutic use Bone metastases In patients with malignant and painful bone disease	Roche
18 700025170	Levonorgestrel	Completed	IV	Levonorgestrel: therapeutic use Prevention of pregnancy Drug utilisation and quality-of-life effects in patients after vaginal delivery	
19 700049741	Levosimendan	Recruiting	IV	Levosimendan: therapeutic use Heart failure In patients with advanced disease; cost-effectiveness trial	
20 700033917	Mannitol	Recruiting	III	Mannitol: therapeutic use Bronchiectasis Efficacy and quality-of-life effects	Pharmaxis
21 700021202	Metoprolol	Recruiting	IV	Metoprolol: therapeutic use	

CTI - PharmacoEconomics February 2010

Secondary prevention of myocardial infarction
In combination with pacemaker in patients with slow heart rates after
myocardial infarction: efficacy and quality-of-life analysis

Adis CTI Record	Drug(s)	Study Status	Study Phase	Headline	Sponsor
22 700046508	Misoprostol Oxytocin	Completed	III	Misoprostol vs oxytocin: therapeutic use Prevention of perioperative haemorrhage, postpartum haemorrhage Cost-effectiveness trial in women undergoing caesarean section	
23 700025898	Sirolimus	Completed	IV	Sirolimus: therapeutic use Prevention of coronary artery restenosis Cost effectiveness of drug-eluting vs bare metal stents in patients with diabetes	Cordis Corporation
24 700043562	Tranexamic-acid	Recruiting	III	Tranexamic acid: therapeutic use Postpartum haemorrhage Evaluating effects on death, hysterectomy and other relevant outcomes: Cost-effectiveness trial	

For further information, please call +44 (0) 20 7981 0765 or send an e-mail to clientsupport@wolterskluwer.com.